Characterization of Asphalt Treated Base Course Material

INE/AUTC 11.0

Pressure Treated Wood

Discusses chemical treatments to increase wood's fire resistance and protect it from rot and termites

Treated inlets

Design of lined ring inlet for reduced noise sound pressure levels of Boeing 707 aircraft engin

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus

Purpose: This paper reports the results of an audit that assessed the prevalence of residual hypertriglyceridemia and the potential need for intensified management among patients with statin-treated type 2 diabetes mellitus (T2DM) in primary care in the UK. Patients and methods: A cross-sectional, observational, systematic audit of patients with diagnosed diabetes from 40 primary care practices was undertaken. The audit collected basic demographic information and data on prescriptions issued during the preceding 4 months. T2DM patients were stratified according to the proportion that attained European Society of Cardiology treatment targets. Results: The audit collected data from 14,652 patients with diagnosed diabetes: 89.5% (n = 13,108) of the total cohort had T2DM. Of the people with T2DM, 22.2% (2916) were not currently receiving lipid-lowering therapy. Up to approximately 80% of these people showed evidence of dyslipidemia. Among the group that received lipid-lowering therapy, 94.7% (9647) were on statin monotherapy, which was usually simvastatin (69.5% of patients receiving statin monotherapy; 6707). The currently available statins were prescribed, with the most common dose being 40 mg simvastatin (44.2%; 4267). Irrespective of the statin used, around half of the patients receiving statin monotherapy did not attain the European Society of Cardiology treatment targets for triglycerides, low-density lipoprotein, high-density lipoprotein, and total cholesterol. Conclusion: T2DM patients managed in UK primary care commonly show persistent lipid abnormalities. Clinicians need to optimize compliance with lipid-lowering and other medications. Clinicians also need to consider intensifying statin regimens, prescribing additional lipid-modifying therapies, and specific treatments aimed at triglyceride lowering to improve dyslipidemia control in statin-treated patients with T2DM

Insecticide treated bednets: A review

The functioning and efficacy of Insecticide Treated Nets (ITNs) in controlling malaria are discussed in the present review. ITNs Insecticide Treated Nets (ITNs) have been shown to have a beneficial impact in reducing malaria mortality and morbidity in children. However, a few issues are still unresolved: for instance the short and long term effects of an artificially induced reduction in the intensity of malaria transmission on the immune system and the mortality of children is not entirely understood; further studies are needed on whether the spread of resistance to pyrethroids, which is the only class of insecticide currently recommended on nets, affects the effectiveness of ITNs so that resistance to these insecticides would constitutes a serious threat for the success of the malaria vector control programs. Lastly, the economic aspects are presented. The main problem is to find a way for a sustainable implementation of this methodology, that includes purchasing new bednets, delivery and the regular re-impregnation of the existing nets. Free delivery and retreatment in poor countries is not only more equitable but also more efficient than marketing methods

Should agency workers be treated differently?

The EU Temporary and Agency Work Directive created a right of equal treatment on working time and pay for agency workers compared to direct workers. This article asks, what justifications are there for any different treatment? Using job security rights as an example, this article explores the framework for regulation of employment agencies and the common law position of agency workers. It highlights, first, that profit-making agencies were frowned on historically by international law, and that principled regulation is required to prevent abuse. It shows, secondly, that the common law test of ‘mutuality of obligation’, that removes employment rights for agency workers, is legally and logically unsound. It then illustrates, third, that a recently developed test for implied contracts, which leads agency workers to have no employer at all, pays incomplete regard to the full authority on contractual and statutory construction. These loopholes are unfair and inefficient and amount to an unjustified subsidy for agency work. Simple recognition is needed that agency workers should not be treated differently, because work through an agency is work like any other

Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation—incidence, location, and severity in cyclosporine- and FK506-treated patients

One hundred and forty randomly selected liver transplant recipients were studied before and after primary orthotopic liver transplantation for the presence or absence of CMV enteritis. Following OLTx, 65 patients were treated with cyclosporine A and 75 were treated with FK506. The two groups were similar with regard to the incidence, location, and outcome of their upper gastrointestinal CMV infection. Prior to OLTx, only one patient had evidence of enteric CMV infection. The incidence of CMV enteritis post-OLTx was 27.7% in the CsA-treated group and 20% in the FK-treated group. During the first posttransplant month, no patient in the FK-treated group developed CMV enteritis, compared with 11.5% of the patients who were treated with CsA (P<0.05). Gastric CMV was found in over 80% of those positive for any organ in either group. In addition to CMV infection of the upper gastrointestinal tract, clinically evident CMV disease involved more nonenteric organs in the CsA-treated group than in the FK-treated group. In the CsA-treated group, CMV-negative patients had a statistically higher 1-year survival rate (100%) than CMV-positive patients (77.8%) (P<0.05). In the FK-treated group, no difference in survival was observed between CMV-positive or CMV-negative cases at 1 year. Of the patients on CsA, 20% received OKT3 for persistent rejection, as compared with 13% in the FK-treated group. The patients receiving both CsA and OKT3 had a higher rate of upper gastrointestinal CMV infection than did FK-treated patients who also received OKT3 therapy (38.5% versus 20%, respectively). Based upon these data, it can be concluded that (1) patients receiving FK have a lower incidence of enteric CMV infection; (2) following OLTx, upper gastrointestinal CMV infection presents later in FK-treated patients; (3) the stomach is the most frequently involved organ in the UGIT; (4) FK-treated liver recipients have less severe enteric CMV infection than do CsA-treated patients; (5) enteric CMV is not a major cause of mortality in liver trans lant recipients; and (6) in patients receiving FK, those who require OKT3 therapy do not appear to be at a greater risk for the development of CMV enteritis than those who do not. © 1992 by Williams & Wilkins